COVID-19 and liver diseases, what we know so far

Mohamed Elnaggar; Ahmed Abomhya; Ismail Elkhattib; Nabila Dawoud; Rajkumar Doshi

doi:10.12998/wjcc.v10.i13.3969

COVID-19 and liver diseases, what we know so far

World J Clin Cases. 2022 May 6;10(13):3969-3980. doi: 10.12998/wjcc.v10.i13.3969.

Authors

Mohamed Elnaggar¹, Ahmed Abomhya², Ismail Elkhattib³, Nabila Dawoud⁴, Rajkumar Doshi⁵

Affiliations

¹ Department of Internal Medicine, University of Nevada Reno School of Medicine, Reno, NV 89052, United States. mohamed.elnaggar.md@gmail.com.
² Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY 11200, United States.
³ Department of Internal Medicine, University of Connecticut, Farmington, CT 06030, United States.
⁴ Department of Internal Medicine, University of Kentucky, Lexington, KY 40508, United States.
⁵ Department of Cardiology, St Joseph's University Medical Center, Paterson, NJ 07503, United States.

Abstract

Coronavirus disease 2019 (COVID-19) pneumonia outbreak started in December 2019. On March 12, 2020, the World Health Organization (WHO) declared that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) constitutes a pandemic, and as of May 2021, SARS-CoV-2 has infected over 167.3 million patients, including 3.4 million deaths, reported to WHO. In this review, we will focus on the relationship between SARS-CoV-2 infection and the liver. We will discuss how chronic liver diseases affect the COVID-19 disease course and outcomes. We will also discuss the SARS-CoV-2 effects on the liver, mechanisms of acute liver injury, and potential management plans.

Keywords: COIVD-19; Hepatocellular carcinoma; Liver diseases; Non alcoholic fatty liver; SARS-CoV-2; Transaminases.

Publication types

Review